Although no direct risk factors for TREM2 and MS have been described, mutations in this receptor and its signalling partners are linked to the rare Nasu–Hakola disease, a disease characterised by frontal lobe dementia, CNS white-matter lesions, and widespread microglia activation [107,108,109]. Here, TREM2 is linked to myeloid sarcoma.